Clinical Trial Update: Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC [Phase 2]

View source ↗

Summary

Phase 2 trial assessing the efficacy and safety of Neo-CRT plus Serplulimab and Nimotuzumab in locally advanced resectable esophageal squamous cell carcinoma. R…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Nimotuzumab (nimotuzumab)
• Serplulimab (serplulimab)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Resectable Esophageal Squamous Cell Carcinoma | Phase 2 | Status: RECRUITING